Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Climb Bio, Inc. Common Stock

CLYM

Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.

Last trade $9.63
Day change -$0.31 (-3.12%)
Day range $9.19 – $10.75
Volume 297,395
Market cap $584M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$583.86M
Price / earnings
—
Price / book
2.56×
Price / sales
—
EV / sales
—
EV / EBITDA
-8.19×

Profitability

Earnings per share
-$1.02
Return on assets
-25.27%
Return on equity
-26.21%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
26.58×
Quick ratio
26.58×
Cash ratio
5.03×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$53.64M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CLYM, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$5.85M$5.65M$5.84M$5.56M$5.82M$4.1M$5.69M$4.95M
Research and development$11.04M$9.71M$9.37M$13.74M$9.07M$6.58M$17.33M$5.96M
Total operating expenses$16.89M$15.36M$15.21M$19.3M$14.89M$10.68M$23.02M$10.91M
Operating income-$16.89M-$15.36M-$15.21M-$19.3M-$14.89M-$10.68M-$23.02M-$10.91M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$15.03M-$13.5M-$13.72M-$17.52M-$12.74M-$8.67M-$20.78M-$8.42M
Income taxes$0$0$0$0$0$0$0$0
Net income-$15.03M-$13.5M-$13.72M-$17.52M-$12.74M-$8.67M-$20.78M-$8.42M
Net income attributable to common shareholders-$15.03M-$13.5M-$13.72M-$17.52M-$12.74M-$8.67M-$20.78M-$8.42M
EBITDA-$16.7M-$15.33M-$15.17M-$19.27M-$14.86M-$10.64M-$23.02M-$10.91M
Basic earnings per share-$0.18-$0.18-$0.20-$0.26-$0.19-$0.13-$0.31-$0.12
Diluted earnings per share-$0.18-$0.18-$0.20-$0.26-$0.19-$0.13-$0.31-$0.12

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026

Climb Bio announced Phase 2 data for budoprutug, an anti-CD19 monoclonal antibody, showing promising results in primary membranous nephropathy (pMN) treatment. The 200 mg dose demonstrated B-cell depletion, 70% PLA2R antibody reduction, and immunologic remission at 12 weeks. Higher 600 mg doses showed greater drug exposure and deeper B-cell depletion. The drug was generally well-tolerated with no serious adverse events. A separate case study showed sustained three-year steroid-free remission in a minimal change disease patient.

GlobeNewswire Inc.

Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight

The idiopathic membranous nephropathy (IMN) market is expected to grow from USD 130 million in 2025 to USD 1 billion by 2036, driven by rising disease prevalence, improved diagnostics, and emerging targeted therapies. Multiple pharmaceutical companies are advancing novel treatments including SNP-ACTH (1-39) Gel, zanubrutinib, obinutuzumab, and povetacicept to address the substantial unmet need for more effective and better-tolerated therapies.

GlobeNewswire Inc.

Climb Bio to Present at Upcoming Investor Conferences

Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company, announced that its executive team will participate in three upcoming healthcare and biotech conferences in February and March 2026, including Guggenheim's Emerging Outlook: Biotech Summit, Oppenheimer's 36th Annual Healthcare Life Sciences Conference, and Leerink Global Healthcare Conference. Live webcasts will be available on the company's investor relations website.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.